Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reslizumab in the treatment of severe eosinophilic asthma: an update.

Immunotherapy - 1 Jun 2018

Walsh Garry M

Abstract excerpt

A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma. Importantly, it is now widely accepted that biologic-based therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma
Share to Biomarkers
Share to Interleukin-5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Antibodies, Monoclonal, Humanized

Share to Anti-Asthmatic Agents

Share to Safety

Share to Treatment Outcome

Source

Identifiers

PMID: 29554826
DOI: 10.2217/imt-2017-0176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reslizumab in the treatment of severe eosinophilic asthma: an update.PMID 29554826Read ↗

What goes up must come down: biomarkers and novel biologicals in severe asthma.Semantic proximity Read ↗

Eosinophilic phenotypes of airway disease.Semantic proximity Read ↗

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read ↗

Reslizumab and Eosinophilic Asthma: One Step Closer to Phenotype-directed Therapy?Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Chronic obstructive pulmonary disease's eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy.Semantic proximity Read ↗

Anti-interleukin-5 therapy in severe asthma.Semantic proximity Read ↗

Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?Semantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Lessons learned from targeting eosinophils in human disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.